In a big boost, Covaxin, Covishield get full market authorisation
New Delhi/IBNS: In a big boost to India's fight against COVID-19, an expert panel of the central drug authority on Wednesday cleared the country's two indigenous vaccines-Covaxin and Covishield-for full use.
The development comes a year after these vaccines' administration on an emergency-use basis started in India.
With this move, the vaccines are expected to be widely available at hospitals and clinics soon, which are registered with the government portal CoWIN.
This will also aid in booster doses, which Prime Minister Narendra Modi announced last month to be administered on health and frontline workers and adults above 60 years of age, as precautionary third doses.
The recommendation by the expert panel of the Central Drugs Standard Control Organisation (CDSCO) has been sent to the top drug regulator DGCI.
"SEC of CDSCO has recommended for the upgrade of Covishield and Covaxin status from restricted use in emergency situations to grant of new drug permission with conditions in the adult population, DCGI will evaluate the recommendations and give its decision," the regulatory body tweeted.
SEC of CDSCO has recommended for upgrade of covishield and covaxin status from restricted use in emergency situations to grant of new drug permission with conditions In adult population ,DCGI will evaluate the recommendations and give its decision.— CDSCO_INDIA_INFO (@CDSCO_INDIA_INF) January 19, 2022
India’s COVID-19 vaccination coverage has crossed 159.54 Crore on Wednesday, the Union Health Ministery stated.
More than 62 lakh vaccine doses have been administered till 7 pm.